Comparison of Overall Survival Associated with Lenalidomide plus Dexamethasone and Bortezomib plus Dexamethasone Among Relapsed / Refractory Multiple Myeloma Patients: A Matched Analysis of Real World and Clinical Trial Populations

被引：0
|
作者：
Nooka, Ajay
Voorhees, Peter M.
Kumar, Shaji K.
Mehra, Maneesha
Lam, Annette
Slavcev, Mary
Potluri, Ravi
Dasgupta, Anandaroop
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3094
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma
    Dimopoulos, Meletios A.
    Orlowski, Robert Z.
    Facon, Thierry
    Sonneveld, Pieter
    Anderson, Kenneth C.
    Beksac, Meral
    Benboubker, Lotfi
    Roddie, Huw
    Potamianou, Anna
    Couturier, Catherine
    Feng, Huaibao
    Ataman, Ozlem
    de Velde, Helgi van
    Richardson, Paul G.
    HAEMATOLOGICA, 2015, 100 (01) : 100 - 106
  • [42] The Impact of Cytogenetics on the Outcomes of Treatment with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma
    Bahlis, Nizar J.
    Song, Kevin W.
    Fu, Tommy
    Roland, Birgitte J.
    Chang, Hong
    Horsman, Doug
    Mansoor, Adnan
    Chen, Christine
    Masih-Khan, Esther
    Trieu, Young
    Bruyere, Helene
    Stewart, Douglas A.
    Reece, Donna E.
    BLOOD, 2008, 112 (11) : 610 - 610
  • [43] LONGER DURATION OF TREATMENT AND MAINTENANCE OF BEST RESPONSE WITH LENALIDOMIDE plus DEXAMETHASONE INCREASES OVERALL SURVIVAL (OS) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    San Miguel, J.
    Dimopoulos, M.
    Bravo, M. -L.
    Weber, D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 382 - 382
  • [44] Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone
    San-Miguel, Jesus F.
    Dimopoulos, Meletios A.
    Stadtmauer, Edward A.
    Rajkumar, S. Vincent
    Siegel, David
    Bravo, Marie-Laure
    Olesnyckyj, Marta
    Knight, Robert D.
    Zeldis, Jerome B.
    Harousseau, Jean-Luc
    Weber, Donna M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (01): : 38 - 43
  • [45] Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM)
    Lacy, Martha Q.
    LaPlant, Betsy R.
    Laumann, Kristina M.
    Kumar, Shaji
    Gertz, Morie A.
    Hayman, Suzanne R.
    Buadi, Francis
    Dispenzieri, Angela
    Lust, John A.
    Kapoor, Prashant
    Leung, Nelson
    Russell, Stephen J.
    Dingli, David
    Gonsalves, Wilson I.
    Fonseca, Rafael
    Bergsagel, P. Leif
    Roy, Vivek
    Sher, Taimur
    Ailawadhi, Sikander
    Chanan-Khan, Asher
    Stewart, A. Keith
    Reeder, Craig B.
    Rajkumar, S. Vincent
    Mikhael, Joseph R.
    BLOOD, 2014, 124 (21)
  • [46] Bortezomib-Based Therapy Following Prior Lenalidomide plus Dexamethasone in Relapsed Multiple Myeloma
    Trieu, Y.
    Xu, W.
    Masih-Khan, E.
    Dean, S.
    Trudel, S.
    Kukreti, V.
    Anglin, P.
    Chen, C.
    Mikhael, J.
    Reece, D.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S53 - S54
  • [47] OVERALL SURVIVAL OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA TREATED WITH CARFILZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE IN THE RANDOMIZED PHASE 3 ENDEAVOR TRIAL
    Dimopoulos, M.
    Goldschmidt, H.
    Niesvizky, R.
    Joshua, D.
    Chng, W. -J
    Oriol, A.
    Orlowski, R.
    Feng, S.
    Kimball, A.
    Moreau, P.
    HAEMATOLOGICA, 2017, 102 : 168 - 168
  • [48] Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial
    Dimopoulos, Meletios A.
    Weisel, Katja
    Lonial, Sagar
    White, Darrell
    Moreau, Philippe
    Mateos, Maria-Victoria
    San-Miguel, Jesus
    Anderson, Kenneth C.
    Shpilberg, Ofer
    Grosicki, Sebastian
    Spicka, Ivan
    Walter-Croneck, Adam
    Magen, Hila
    Belch, Andrew
    Reece, Donna
    Beksac, Meral
    Ganetsky, Alex
    Jou, Ying-Ming
    McKiver, Mihaela Popa
    Singhal, Anil K.
    Richardson, Paul G.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E15 - E16
  • [49] Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed multiple myeloma (IKEMA): final overall survival analysis
    Yong, Kwee
    Martin, Thomas
    Dimopoulos, Meletios
    Mikhael, Joseph
    Capra, Marcelo
    Facon, Thierry
    Hajek, Roman
    Spicka, Ivan
    Baker, Ross
    Kim, Kihyun
    Martinez, Gracia
    Min, Chang-Ki
    Pour, Ludek
    Leleu, Xavier
    Oriol, Albert
    Koh, Youngil
    Suzuki, Kenshi
    Casca, France
    Mace, Sandrine
    Risse, Marie-Laure
    Moreau, Philippe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S30 - S31
  • [50] Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status.
    Weisel, Katja C.
    Miguel, Jesus San
    Cook, Gordon
    Leiba, Merav
    Suzuki, Kenshi
    Kumar, Shaji
    Cavo, Michele
    Avet-Loiseau, Herve
    Quach, Hang
    Hungria, Vania
    Lentzsch, Suzanne
    Hajek, Roman
    Sonneveld, Pieter
    Wu, Kaida
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345